Indications for TEE Before Cardioversion for Atrial Fibrillation: Implications for Appropriateness Criteria  by Grewal, Gaganpreet K. et al.
a
C
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 5 , N O . 6 , 2 0 1 2
© 2 0 1 2 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 1 . 1 2 . 0 2 0B U S I N E S S A N D A D V O C A C Y
Indications for TEE Before Cardioversion for
Atrial Fibrillation: Implications for
Appropriateness Criteria
Gaganpreet K. Grewal, BS,* Tristan B. Klosterman, BS,* Kevin Shrestha, BS,*
Hirad Yarmohammadi, MD,* Andrew O. Zurick, MD,* Brandon C. Varr, MD,†
W. H. Wilson Tang, MD,* Bruce D. Lindsay, MD,* Allan L. Klein, MD*
Cleveland, Ohio; and Stanford, CaliforniaJACC: CARDIOVASCULAR
IMAGING CME
CME Editor: Ragaven Baliga, MD
This article has been selected as this issue’s CME activity,
available online at www.imaging.onlinejacc.org by select-
ing the CME tab on the top navigation bar.
Accreditation and Designation Statement
The American College of Cardiology Foundation
(ACCF) is accredited by the Accreditation Council
for Continuing Medical Education (ACCME) to
provide continuing medical education for physicians.
The ACCF designates this Journal-based CME
ctivity for a maximum of 1 AMA PRA Category 1
redit(s)™. Physicians should only claim credit com-
mensurate with the extent of their participation in
the activity.
Method of Participation and Receipt of CME
Certificate
To obtain credit for this CME activity, you must:
1. Be an ACC member or JACC: Cardiovascular
Imaging subscriber.
2. Carefully read the CME-designated article avail-
able online and in this issue of the journal.
3. Answer the post-test questions. At least 2 out of
the 3 questions provided must be answered cor-
rectly to obtain CME credit.Stanford Hospital and Clinics, Stanford, California. Dr. Tang is a
consultant for Medtronic Inc. and St. Jude Medical. All other5. Claim your CME credit and receive your certif-
icate electronically by following the instructions
given at the conclusion of the activity.
CME Objective for This Article: At the end of this
activity the reader should be able to: 1) evaluate
appropriateness of transesophageal echocardiogra-
phy before direct current cardioversion of atrial
fibrillaton; 2) enumerate the indications for trans-
esophageal echocardiography before direct current
cardioversion of atrial fibrillaton; and 3) determine
risk of thrombus and systemic thromboembolism
based on the indications for transesophageal echo-
cardiography.
CME Editor Disclosure: JACC: Cardiovascular
Imaging CME Editor Ragaven Baliga, MD, has
reported that he has no relationships to disclose.
Author Disclosure: Dr. Tang is a consultant for
Medtronic Inc. and St. Jude Medical. All other
authors have reported that they have no relation-
ships relevant to the contents of this paper to
disclose.
Medium of Participation: Print (article only);
online (article and quiz).
CME Term of Approval:
Issue Date: June 2012
Expiration Date: May 31, 2013
authors have reported that they have no relationships relevant to the
contents of this paper to disclose.4. Complete a brief evaluation.
From the *Department of Cardiovascular Medicine, Cleveland
Clinic, Cleveland, Ohio; and the †Department of Medicine,Manuscript received July 18, 2011; revised manuscript received
November 7, 2011, accepted December 22, 2011.
DJ A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 6 , 2 0 1 2
J U N E 2 0 1 2 : 6 4 1 – 8
Grewal et al.
Indications for TEE Before Cardioversion
642Indications for TEE Before Cardioversion for Atrial Fibrillation:
Implications for Appropriateness Criteria
The purpose of this study was to evaluate appropriateness of transesophageal echocardiography
(TEE) before direct current cardioversion (DCC), investigate indications for TEE, and analyze if
indications are predictive of outcome. According to American College of Cardiology Foundation/
American Society of Echocardiography 2011 Appropriateness Criteria, TEE is appropriate in the
evaluation of patients with atrial ﬁbrillation (AF) to facilitate clinical decision making with regards
to anticoagulation and/or DCC. However, it is unclear in which instances physicians utilize TEE. We
reviewed 671 TEE studies in 604 AF patients (age 66  13 years, 67% male) in which TEE was
performed before DCC for left atrial thrombus (LAT)/sludge. Studies were divided by the main
indication for TEE into the following 8 categories: 1) congestive heart failure (CHF)/hemodynamic
compromise; 2) symptomatic; 3) new onset AF; 4) hospitalized and symptomatic; 5) high stroke risk;
6) subtherapeutic anticoagulation; 7) miscellaneous; and 8) inappropriate for TEE. The main
indications for TEE before DCC were symptomatic (26.4%) and CHF/hemodynamic compromise
(26.1%). We deemed 2.7% of the studies as inappropriate. LAT/sludge was found in 8.2% of studies.
Incidence of LAT/sludge differed signiﬁcantly between indications (p  0.0021) and the highest
incidences occurred in the high stroke risk (17.6%) and hospitalized and symptomatic (14.1%)
categories. No LAT/sludge was found in the miscellaneous or inappropriate groups. Stroke occurred
in 2.5% (n  15) of all patients and in all groups except for miscellaneous and inappropriate (p 
0.3). TEE is appropriately used prior to DCC for patients with the main indications of symptomatic
and CHF/hemodynamic compromise. In a minority of studies, TEE utilization was inappropriate.Incidence of LAT/sludge differed between indications.
6
p
Jirect current cardioversion (DCC)
is an important treatment meth-
od for atrial fibrillation (AF);
however, there is a significant
risk of stroke and other systemic
thromboembolism after DCC. To de-
crease this risk, patients have conven-
tionally been anticoagulated to achieve
an international normalized ratio
(INR) of 2 to 3 for 3 weeks before
DCC. More recently, transesophageal
echocardiography (TEE) before DCC
has been shown to be as effective as
conventional anticoagulation in pre-
venting stroke while also expediting
DCC (1). TEE-guided cardioversion
may be a better option than conven-
tional therapy in certain patients,
such as those who are highly symp-
tomatic, hemodynamically compro-
mised, newly diagnosed with AF, or
have a high risk of stroke.By 1998, TEE-guided DCC was
performed in 12.1% of cases, and 38%
of the practices surveyed were using
TEE for 5% of DCC cases (2). Since
that time, TEE-guided cardioversion
has become increasingly popular, and
costs of diagnostic imaging in general
have increased rapidly, prompting the
development of appropriateness criteria
(3). The American College of Cardiol-
ogy Foundation/American Society of
Echocardiography (ACCF/ASE) 2011
Appropriateness Criteria address TEE-
guided cardioversion similarly as fol-
lows: appropriate, “evaluation to facili-
tate clinical decision making with
regards to anticoagulation, cardiover-
sion, and/or radiofrequency ablation”;
and inappropriate, “evaluation when a
decision has been made to anticoag-
ulate and not to perform cardiover-
sion” (4). sLittle is known about the clinical
settings in which physicians are using
TEE-guided DCC or if TEE-guided
DCC is being overused in situations in
which conventional therapy would be
preferred. Therefore, our objectives
were: 1) to investigate if TEE-guided
DCC is being used appropriately; 2) to
evaluate indications for which patients
are receiving TEE; and 3) as a second-
ary endpoint, to analyze the risk of
thrombus and systemic thromboembo-
lism on the basis of the indication for
TEE.
Methods
Patients. We retrospectively analyzed
71 TEE-guided DCCs (604 unique
atients; 67% male) performed from
anuary 2007 to December 2008. The
tudy was approved by the local insti-
12
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643tutional review board. Clinical data,
such as age, sex, components of the
CHADS2 score, and incidence of fu-
ture thromboembolic events, were col-
lected from patient medical charts. A
CHADS2 score ranging from 0 to 6
was calculated for each patient at the
time of TEE, as follows: congestive
heart failure (CHF), 1 point; hyperten-
sion, 1 point; age 75 years, 1 point;
diabetes mellitus, 1 point; and history
of stroke, transient ischemic attack, or
systemic thromboembolism, 2 points.
TEE and transthoracic echocardiography.
TEE study reports were reviewed for
left ventricular ejection fraction
(LVEF) (if a transthoracic echocardi-
ography was not done within 24 h of
the TEE); presence of left atrial throm-
bus (LAT); sludge; and/or spontaneous
echo contrast. Thrombus was defined
as a circumscribed and uniformly echo-
dense intracavitary mass distinct from
the underlying left atrium or the left
atrium appendage endocardium and
pectinate muscle that is present in 1
imaging plane (5). Sludge was defined
as a dynamic gelatinous, precipitous
echodensity, without a discrete mass,
and present throughout the cardiac cy-
cle. Spontaneous echo contrast was de-
fined as dynamic smoke-like echoes
with characteristic swirling motion
with an optimal gain setting during the
cardiac cycle. When available, trans-
thoracic echocardiography reports were
reviewed for the left atrial area.
Indications and deﬁnitions. Patient
charts were reviewed for indications for
TEE. These indications were catego-
rized as being “appropriate,” “inappro-
priate,” or “unable to be classified” by
applying the ACCF/ASE 2011 Appro-
priateness Criteria (4). Studies were
labeled “unable to be classified” due to
insufficient documentation and were
excluded from further analysis.
Studies were further sorted according
to the main indication for use of TEE
into 7 appropriate categories and 4 inap-
propriate categories that are defined here
as well as listed in Table 1 (6).Appropriate:
. “CHF/hemodynamic compromise”
included patients with current
CHF exacerbation or hemody-
namic instability. This indication
did not include patients with a
history of CHF that was currently
well compensated.
. “Symptomatic” included patients
who were having significant symp-
toms of AF, including palpitations,
chest pain, dyspnea, fatigue, light-
headedness, or syncope (7). This
indication did not include patients
who were already hospitalized or
patients who were diagnosed for
the first time with AF.
. “Hospitalized and symptomatic”
included patients who were hospi-
talized for a reason other than AF
and who developed symptomatic
AF during admission.
. “New-onset” AF included pa-
tients who were diagnosed for the
first time with AF and who were
in AF for 48 h.
5. “High stroke risk” included patients
with a history of stroke, transient
ischemic attack, previous LAT, hy-
pertrophic obstructive cardiomyop-
athy, or rheumatic fever (7).
6. “Subtherapeutic anticoagulation”
Table 1. Appropriate and Inappropriate
Indications for TEE-Guided DCC
Appropriate indications
CHF/hemodynamic compromise
Symptomatic
Hospitalized and symptomatic
New-onset AF
High stroke risk
Subtherapeutic anticoagulation
Miscellaneous
Inappropriate indications (not indicated)
Stable with therapeutic anticoagulation
3 weeks
AF 48 h
Permanent AF
Hospitalized but asymptomatic
Adapted from Asher et al. (6).
AF  atrial ﬁbrillation; CHF  congestive heart failure;
DCC  direct current cardioversion; TEE  transesopha-
geal echocardiography.included patients who were under-going conventional anticoagulation
but had a documented INR 2 at
any point in the last 3 weeks and
who did not already have one of the
indications defined here.
7. “Miscellaneous” included patients
who received TEE for a reason
unrelated to AF that is found else-
where in the appropriateness crite-
ria, such as evaluation of valve func-
tion or endocarditis. The timing of
the TEE coincidentally happened
to help expedite DCC.
Inappropriate:
1. “Stable with therapeutic anticoagu-
lation 3 weeks” included patients
who were hemodynamically stable
and who were therapeutically anti-
coagulated for at least 3 weeks.
These patients completed the con-
ventional method of risk reduction
for thromboembolism and did not
need TEE (7).
2. “AF 48 h” included patients with
no history of AF and who were in
AF for 48 h. It was believed that
there was not enough time for a
thrombus to form and therefore
TEE was not useful (7,8).
3. “Permanent AF” included patients
in whom sinus rhythm was unable
to be sustained after cardioversion
or in whom the physician and pa-
tient decided to accept AF (7).
These patients were not indicated
for TEE or DCC.
4. “Hospitalized but asymptomatic”
included patients who were hospi-
talized and in AF but were not
having symptoms, CHF exacerba-
tion, or hemodynamic compromise.
These patients were able to be
managed with 3 weeks of antico-
agulation.
Often, patients had 1 indication
for TEE. To determine the main indi-
cation, categories were ranked as fol-
lows: 1) CHF/hemodynamic compro-
mise; 2) hospitalized and symptomatic;
3) new onset; 4) symptomatic; 5) sub-
therapeutic anticoagulation; 6) miscel-
t
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644laneous; and 7) high stroke risk (ranked
first if patient had history of LAT).
Thromboembolic events. Incidence of
thromboembolic events, including
stroke, transient ischemic attack, or any
other systemic embolization as a sec-
ondary endpoint, was determined by
retrospective chart review.
Statistical analysis. Continuous vari-
ables were summarized as mean  SD.
Categorical and ordinal variables were
reported as frequencies and percent-
ages. Patient characteristics, TEE char-
acteristics, and outcome variables were
compared across indications using lin-
ear and logistics regression models as
appropriate. CHADS2 scores were
compared across categories by using
the Kruskal-Wallis test. A p value
0.05 was considered statistically
significant. Statistical analysis was
performed using Stata version 11
(StataCorp LP, College Station,
Texas).
Results
Patient characteristics. Patient charac-
eristics are shown in Table 2. The
ean patient age was 66  13 years,
nd 67.7% of patients were male. The
ean CHADS2 score was 2.01 1.27.
LVEF was measured in 80.9% of stud-
ies (n  533), and mean LVEF was
43.5  14.6%. There were no signifi-
cant differences across indications relat-
ing to sex, hypertension, valvular disease,
or left atrium area. However, there were
significant differences between indica-
tions regarding CHADS2 scores, age,
HF, diabetes mellitus, history of
troke, and LVEF.
Appropriateness and indications. Of the
71 studies performed before DCC,
39 (95.2%) were appropriate, 18
2.7%) were inappropriate, and 12
1.8%) were unable to be classified due
o insufficient documentation.
The categories of symptomatic
26.4%; n  174) and CHF/hemo-
ynamic compromise (26.1%; n 174)
omprised the main indications forTEE before DCC. All 4 inappropriateT M A
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645indications together comprised 2.7%
(n  18) of studies: stable with thera-
eutic anticoagulation 3 weeks, n 
1; AF 48 h, n  3; permanent AF,
 2; and hospitalized but symptom-
tic, n  2 (Fig. 1).
Thrombus and sludge. LAT/sludge was
ound in 8.19% (n  54) of 659 clas-
ifiable TEE studies. Incidence of
AT/sludge was significantly different
etween different indications (p 
.0021), with the highest incidences
eing in the high stroke risk (17.65%)
nd hospitalized and symptomatic
14.08%). The lowest incidences oc-
New
Onset AF
79 (12.0%)
Hospitalized
and Symptomatic
71 (10.8%)
Symptomatic
174 (26.4%)
Figure 1. Indications for TEE Before DCC
Proportions of transesophageal echocardiography (
into the categories shown on the right. AF  atrial
0
CHF/Hemodynamic Compromise
Symptomatic
New Onset AF
Hospitalized and Symptomatic
High Stroke Risk
Subtherapeutic Anticoagulation
Miscellaneous
Not Indicated
                   
                  3
                   
                   
                   
                   
0
0
P
In
di
ca
tio
n
Figure 2. Prevalence of LAT/Sludge
The x-axis represents the percentage of TEE studies w
(LAT)/sludge. There is a signiﬁcant difference in preva
Abbreviations as in Figure 1.urred in the indications of new onset
5.06%), miscellaneous (0%), and inap-
ropriate (0%) (Fig. 2). Outside the
igh stroke risk group, no patients with
AT received DCC, and 1 patient
ith sludge received DCC.
In the high stroke risk group, there
ere 12 studies with LAT/sludge (11
ith LAT and 1 with sludge). Cardio-
ersion was performed in 3 patients
ith LAT/sludge, all of whom had a
istory of LAT, had been receiving
herapeutic anticoagulation for 3
eeks, and who were also in CHF or
ymptomatic from AF. Only 4 patients
gh Stroke Risk
68 (10.3%)
Subtherapeutic
Anticoagulation
56 (8.5%)
Miscellaneous
21 (3.2%)
Not Indicated
18 (2.7%)
AF <48 hou
3 (0.5%)
CHF/
odynamic
mpromise
2 (26.1%)
Stable with T
Anticoagulatio
11 (1.
studies performed for different indications are repre
illation; CHF  congestive heart failure; DCC  direc
                            10.47
5.06
                                               14.08
                                                                 17.65
           7.14
entage With Thrombus/Sludge
10 15 20
n each indication revealing left atrial thrombus
e of LAT/sludge between indications (p  0.0021).n the high-risk group did not have a
herapeutic INR at time of TEE, and 8
atients had a subtherapeutic INR in
he 3 weeks preceding TEE.
Of the studies with LAT/sludge,
3.3% were found in studies for CHF/
emodynamic compromise, 22.2% in
igh stroke risk, 18.5% in hospitalized
nd symptomatic, 11.1% in symptom-
tic, 7.4% in new onset, and 7.4% in
ubtherapeutic anticoagulation.
Thromboembolism. After a mean follow-
p of 17.9 months, thromboembolism
ccurred in 2.5% (n  15) of patients
nd occurred in all indication groups
xcept miscellaneous and inappropri-
te, although this was not statistically
ignificant (p  0.3) (Fig. 3). One
hromboembolic event occurred 3 days
fter DCC, while the remainder oc-
urred 2 to 18 months after DCC. In
he high stroke risk group, 4 thrombo-
mbolic events occurred, although
one was within 3 days of DCC.
Discussion
Despite the ACCF/ASE 2011 Appro-
priateness Criteria addressing TEE in
the setting of AF (4), it is still not clear
in which clinical situations TEE is
more appropriate. The current con-
cerns are whether we can better identify
Permanent AF
2 (0.3%)
Hospitalized but
Asymptomatic
2 (0.3%)
apeutic
3 Weeks
ted. Inappropriate studies were further classiﬁed
rrent cardioversion.Hi
rs
Hem
Co
17
her
n >
7%)
TEE) sen       
.45
       
       
       
       
5
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lencclinical situations for which TEE is
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646best suited and if perhaps TEE is being
overutilized. Academic centers with
high volumes of DCC (such as our
institution) may be prone to overuti-
lization of TEE because these types of
centers are more likely to perform a
larger proportion of DCCs with TEE
guidance (2). Therefore, this study ex-
amined the indications for which
TEE-guided DCC was being per-
formed.
Our study found that: 1) the vast
majority of TEEs performed before
DCC are appropriate under the current
criteria; 2) the most frequent indica-
tions are CHF/hemodynamic compro-
mise and symptomatic, suggesting that
TEE is being used to expedite the
DCC process; and 3) the prevalence of
LAT/sludge differs among indications
for TEE.
The fact that approximately one-half
of all TEEs were performed for the
indications of CHF/hemodynamic
compromise and symptoms suggests
that TEE is being used to expedite
DCC by avoiding prolonged anticoag-
ulation until a therapeutic INR is
maintained for 3 consecutive weeks.
Although conventional therapy dictates
3 weeks, it often takes longer to achieve
this goal, as evidenced by the ACUTE
(Assessment of Cardioversion Using
Transesophageal Echocardiography)
0
CHF/Hemodynamic Compromise
Symptomatic
New Onset AF
Hospitalized and Symptomatic
High Stroke Risk
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Not Indicated
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Figure 3. Incidence of Thromboembolism
The x-axis represents the incidence of future throm
incidence did not differ signiﬁcantly between indictrial, in which patients undergoing con-ventional therapy waited 30.6  10.6
days for DCC (9). In addition, in an
8-week follow-up of functional status,
the ACUTE trial found that TEE-
guided DCC was a predictor for im-
provement in functional status (10).
The trial also found that patients with
CHF had a greater improvement in
functional status than did patients
without CHF.
The third most common indication
was new-onset AF (12%). TEE-guided
cardioversion may be beneficial in these
patients because it helps prevent atrial
remodeling that may occur while wait-
ing for a therapeutic INR. It is known
that prolonged AF results in atrial en-
largement in humans (11). The
ACUTE study also found that sinus
rhythm is more likely to be maintained
in patients undergoing TEE-guided
DCC than in patients undergoing
DCC after conventional anticoagula-
tion (1).
Those patients with the indication of
high stroke risk may benefit from TEE,
especially if they have a history of
LAT/sludge, to evaluate for the serial
resolution of LAT/sludge. Although
we considered it appropriate to use
TEE to screen for LAT/sludge in pa-
tients with a history of LAT/sludge,
not all groups believe this is currently
addressed in the ACCF/ASE 2011
.3
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5 10
mbolic events within each indication. The
s (p  0.3). Abbreviations as in Figure 1.Appropriateness Criteria. A Universityof Chicago group found that many of
the TEEs at their institution were per-
formed to evaluate for resolution of
LAT/sludge but felt that this use was
not addressed in the current appro-
priateness criteria (12). Regardless of
the criteria, both the University of
Chicago and our group agree that this
is an appropriate use. In fact, a
follow-up TEE to detect residual LAT
may be more cost-effective than as-
suming 4 weeks of anticoagulation is
sufficient, although this is highly de-
pendent on the risk of post-cardioversion
stroke (13).
Those patients with the indication of
subtherapeutic anticoagulation would
benefit from TEE because it has been
shown that the incidence of LAT/
sludge is higher in this group (14).
TEE allows these patients to finally
receive DCC with the same risk reduc-
tion that successful anticoagulation
would have provided. The least com-
mon indications were miscellaneous
and inappropriate. The low incidence
of inappropriate findings is reassuring.
The most common inappropriate in-
dication was stable with therapeutic
anticoagulation 3 weeks (11 of 18
inappropriate studies), serving as a re-
minder to check INR history before
performing TEE. There were 3 studies
performed with the indication of AF
48 h. It is generally accepted that
48 h is not enough time to form LAT/
sludge, although LAT/sludge has been
reported in patients with AF 48 h
(15). There were 2 TEE-guided DCCs
performed on patients with permanent
AF. Both patient and physician have
accepted remaining in AF. Therefore,
it is unlikely that DCC should be
performed on these patients, much less
a TEE-guided approach.
A full one-third (18 of 54) of the
studies revealing LAT/sludge were
found in the CHF/hemodynamic com-
promise group. This finding suggests
that TEE is especially useful in screen-
ing patients with CHF/hemodynamic
compromise because it is a group with a     2
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thromboembolic risk.
The highest prevalence of LAT/
sludge was found in the indications of
high stroke risk and hospitalized and
symptomatic, suggesting that these 2
groups also benefit from TEE. This
finding is not particularly surprising
because it shows that sicker patients
tend to be at higher risk for LAT/
sludge. It is reassuring that none of the
studies in the not indicated category
revealed LAT/sludge; however, there
were only 18 studies.
Study limitations. This study was retro-
pective and depended on documenta-
ion in patient charts. Follow-up may
ave been incomplete in our referred
atient population. Practice at our in-
titution may not reflect the practice at
ther centers, but we are a high-volume
enter for TEE-guided DCC and see a
ariety of patients. Almost all TEEs
rdered before DCC at our institution
re ordered by a cardiologist, and the
ecision to pursue TEE-guided DCC
r traditional anticoagulation is left to
he physician’s clinical judgment. The
ategories used in the study are arbi-phy, American Heart Association, Americanroups; however, they were based on
revious experience with TEE-guided
ardioversions (10). Due to the low
ncidence of thromboembolic events,
his study was not sufficiently powered
o correlate indications with thrombo-
mbolism. A larger study would be
eeded to determine which indications
ave an increased risk of post-DCC
hromboembolism. Additional studies
ill be needed to address the role of
ew anticoagulants in TEE-guided
CC (16).
Clinical implications. Appropriateness
criteria are often a combination of evi-
dence and consensus among experts.
This study adds evidence to the criteria.
Furthermore, it also clarifies the appli-
cability of the criteria by providing
better described indications. In addi-
tion, it reveals the indications for which
physicians are using TEE-guided car-
dioversion and is a step in further
stratifying which patients are more
likely to benefit from TEE.
Conclusions
Our study found that TEE is beingguidelines (writing committee to revise the
2001 guidelines for the management of pa-making before DCC, with the main
indications being symptomatic and
CHF/hemodynamic compromise. The
study also found that one-third of stud-
ies with LAT/sludge were found in
patients with the indication of CHF/
hemodynamic compromise and that
the highest prevalence of LAT/sludge
was in patients who received TEE for
the indication of high stroke risk or
hospitalized and symptomatic. Our
study did not reveal any LAT/sludge in
inappropriate studies; however, there
were very few inappropriate studies
conducted. Due to the low incidence of
future thromboembolic events, a larger
study will be needed in the future to
correlate indications for TEE-guided
DCC to outcomes.
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